Recent Updates
Recently added Catalysts

Arista

Phase 1

Blood Loss, Surgical | Small molecule | Other |Becton, Dickinson and Company|Last Updated: Sep 19, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedNO_TREATMENT_CONTROLLEDDMC
Total Trials1
Total Enrollment61

FDA Designations

No designations recorded

Clinical trial landscape

Arista · 1 trial · 1 indication

Phase 1 1
NCT05522153Arista Hemostatic Powder for Total Knee Post Operative Outcomes StudyBlood Loss, Surgical
COMPLETED61 Analytics
PHASE1COMPLETED
Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study
Blood Loss, SurgicalUnlock trial analytics

Study Endpoints

Primary Endpoints

Blood Loss
Time of incision until 90 days post-op

Calculated on standard hospital protocol

Secondary Endpoints

Thigh Circumference
3 months post op
Range of Motion
3 months post op
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Arista groupEXPERIMENTALthis group of randomized patients will receive 5 grams of arista hemostatic powder intra-operatively in their wound in addition to 1 gram of IV transexemic acid prior to incision
control groupNO_INTERVENTIONthis group of randomized patients will receive just the 1 gram of IV transexemic acid prior to incision

Interventions

NameTypeDescription
AristaDRUGhemostatic powder
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * • They willingly desire to participate and signed the informed consent * Are between the ages of 18 and 100 years of age * Have the mental capacity to provide consent * Are undergoing a primary unilateral total knee arthroplasty Exclusion Criteria: * • allergy to Aris...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Arista

What is Arista used for?

Arista is a small molecule drug being developed for surgical blood loss. It is currently in Phase 1 clinical development as an investigational therapy. The drug is intended to address blood loss that occurs during surgical procedures.

Who makes Arista?

Arista is being developed by Becton, Dickinson and Company, a company traded on the New York Stock Exchange under the ticker symbol BDX. The company is conducting clinical research to evaluate the drug's safety and efficacy in surgical settings.

What phase is Arista in?

Arista is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for its potential to manage surgical blood loss, with one clinical trial completed to date.

What clinical trials is Arista in?

Arista has been studied in one clinical trial registered as NCT05522153, titled "Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study." This Phase 1 trial was completed in the United States and enrolled 61 participants, including healthy volunteers aged 18 years and older.

Is Arista the same as Arista Hemostatic Powder?

Yes, Arista is also known as Arista Hemostatic Powder, as referenced in the clinical trial title. The drug is being evaluated for its hemostatic properties, which relate to controlling bleeding, specifically in the context of surgical procedures.